Table 1.
Baseline characteristics of patients enrolled in the study.
| Baseline characteristic | N=19, n (%) |
|---|---|
| Age, median in years (range) | 42 (19–69) |
| Sex | |
| Male | 8(42) |
| Female | 11(58) |
| Race | |
| White | 13(68) |
| Asian | 4(21) |
| Other | 2(11) |
| Smoking history | |
| Never | 14(74) |
| Light (≤ 10 pack-years) | 4(21) |
| Heavy (>10 pack-years) | 1(5) |
| Histology | |
| Adenocarcinoma | 19(100) |
| Stage at diagnosis# | |
| III | 7(37) |
| IV | 12(63) |
| Alectinib line of therapy | |
| First | 2(11) |
| Second | 8(42) |
| Third | 5(26) |
| Fourth or greater | 4(21) |
| Symptomatic CNS metastases | |
| No | 11(58) |
| Yes | 8(42) |
| Size of largest brain metastasis | |
| < 1 cm | 3(16) |
| 1 cm to < 2 cm | 10(53) |
| ≥ 2 cm | 6(32) |
| Leptomeningeal disease | |
| No | 15(79) |
| Yes | 4(21) |
| Radiation therapy | |
| No prior brain radiation | 11(58) |
| Prior brain radiation | 8(42) |
| Type of brain RT | |
| Prior WBRT | 4(21) |
| Prior brain SRS | 3(16) |
| Prior WBRT and SRS | 1 (5) |
| RT to alectinib interval | |
| Within 4 weeks | 0 |
| > 4 weeks to ≤6 months | 1(5) |
| > 6 months | 7(37) |
#
Staging per the American Joint Committee on Cancer 7th edition.
Abbreviations: CNS, central nervous system; RT, radiation therapy; WBRT, whole brain radiotherapy; SRS, stereotactic radiosurgery